Paediatric Vaccine Market: Pneumococcal Indication Segment Anticipated to Be the Most Attractive Segment Through 2026: Global Industry Analysis and Opportunity Assessment, 2016-2026

NEW YORK, Jan. 11, 2017 /PRNewswire/ -- Global Paediatric Vaccine Market: Towards a better and safer tomorrow

Paediatric vaccines are administered to a child in its paediatric age which is from 0 – 18 years of age. Vaccines are generally given in order to prevent children from diseases transferred through infections, seasonal variations and even through unhygienic areas. Depending upon disease, the vaccines are administered at regular intervals. WHO has designed a standard immunization program in order to have desired time interval between vaccines doses.

Paediatric vaccines considered in the report include pneumococcal vaccine, DTP vaccine, rotavirus vaccine, MMR vaccine, polio vaccine, influenza vaccine, hepatitis B vaccine, Hib vaccine and meningococcal vaccine. Pneumococcal vaccine is administered to prevent the child from infectious diseases such as pneumonia. DTP vaccines is a combination vaccine administered against prevention of three diseases those are diphtheria, tetanus and pertussis. Hib vaccine is also a combination vaccine for hepatitis B and influenza and is widely accepted.

The market to expand manifold during the forecast period (2016 - 2026)

In terms of revenue, the global paediatric vaccine market is projected to expand at a CAGR of 12.2% during the forecast period and is expected to be valued at US$ 88.14 Bn by the end of 2026.

Revamped government policies to benefit the market, though soaring prices of vaccines to play spoilsport

The growth of the global paediatric vaccine market is primarily driven by increasing awareness regarding benefits of vaccination in prevention of diseases, rising economic growth, the collaboration of national manufacturers with key players in view to provide high-quality vaccines in at remote areas and initiative by global key players in developing innovative vaccines. In addition favourable reimbursement and increasing government support is expected to fuel the market growth over the forecast period. However, rising cost of vaccines, low accessibility to remote areas and increasing the availability of biosimilars at low rates might hinder the market growth over the forecast period.

The Pneumococcal segment to act as a catalyst in the overall market growth

Based on indication, the global paediatric vaccine market is segmented into pneumococcal vaccine, DTP vaccine, rotavirus vaccine, MMR vaccine, polio vaccine, influenza vaccine, hepatitis B vaccine, Hib vaccine and meningococcal vaccine. In terms of revenue share, the pneumococcal segment dominated the global paediatric vaccine market in 2015 and is expected to reach the cusp within the forecast period. The Hib segment is expected to witness relatively higher growth rates in terms of value in the global paediatric vaccine market over the forecast period.

Recombinant segment to face steep competition from the Conjugate segment within the forecast period

Based on technology, the global paediatric vaccine market is segmented into live or attenuated vaccine, inactivated or killed vaccines, conjugate vaccine, toxoid vaccine, subunit vaccine and recombinant vaccine. In terms of revenue share, the conjugate segment dominated the global paediatric vaccine market in 2015 and is expected to maintain the spike throughout the forecast period, registering higher CAGR as compared to the recombinant segment.

Monovalent vaccine segment to accumulate maximum market share

Based on vaccine type, the global paediatric vaccine market is segmented into monovalent vaccines and multivalent vaccines. Among these, monovalent vaccine segment held maximum market share in 2015 and expected to continue the trend throughout the forecast period.

The Institutional Health Centres segment to topple Hospital Pharmacy segment in the forecast period

Based on end user, the global paediatric vaccine market is segmented into hospital pharmacies, retail pharmacies and institutional health centres. Currently, institutional health centres segment accounts for relatively higher revenue share, followed by hospital pharmacy end user segment.

North America market to lead the pack
The global paediatric vaccine market is segmented into seven major regions: North America, Latin America, Western Europe, Eastern Europe, APEJ (Asia Pacific excluding Japan), Japan and the Middle East & Africa (MEA). In terms of value, North America is expected to be the dominant regional market by 2016 end and is expected to expand at a CAGR of 11.0% over the forecast period. APEJ is expected to be the fastest growing market in terms of revenue growth in the global paediatric vaccine market, registering a CAGR of 14.9% over the forecast period.

Key stakeholders to create clamour in the market through mergers and revamped investment policies

Some key players in the global paediatric vaccine market included in this report are GlaxoSmithKline Plc., Merck & Co., Inc., Pfizer Inc., Sanofi, Panacea Biotec, Zydua Cadila, Emergent BioSolutions Inc., Serum Institute of India Pvt. Ltd., Bharat Biotech and Indian Immunologicals Ltd.

Read the full report: http://www.reportlinker.com/p04598103-summary/view-report.html

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

http://www.reportlinker.com


__________________________
Contact Clare: clare@reportlinker.com
US: (339)-368-6001
Intl: +1 339-368-6001

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/paediatric-vaccine-market-pneumococcal-indication-segment-anticipated-to-be-the-most-attractive-segment-through-2026-global-industry-analysis-and-opportunity-assessment-2016-2026-300389812.html

SOURCE Reportlinker